AD/PD 2027 · BarcelonaACCEPTED
Plasma-CSF Concordance of 129 Neurodegeneration Proteins: Only pTau-217 Variants Translate
Biomarkers
AD/PD 2027 · BarcelonaACCEPTED
Plasma pTau217 Platforms Perform Equivalently and Outperform pTau181 for Detecting CSF Amyloid Positivity
Biomarkers
AD/PD 2027 · BarcelonaACCEPTED
Plasma pTau217, Aβ42-to-Aβ40 Ratio, NfL, and GFAP Improve CSF Amyloid-Positivity Discrimination Beyond Clinical and Genetic Predictors
Biomarkers
AD/PD 2027 · BarcelonaACCEPTED
Cross-Platform CSF Proteomics: ACHE and YWHAE Replicate on Aptamer and Mass-Spectrometry Platforms
Proteomics
AD/PD 2027 · BarcelonaACCEPTED
CSF proteomics study · title available on request
Proteomics
AD/PD 2027 · BarcelonaACCEPTED
Serum Phosphatidylcholines and Serotonin Differ in Alzheimer Dementia But Add No Incremental Classification Value
Metabolomics
AD/PD 2027 · BarcelonaACCEPTED
Network Propagation from Alzheimer-Associated Genes Enriches Therapy Controls and Prioritizes Kinase and Phagocytosis Pathways
Genomics
AD/PD 2027 · BarcelonaACCEPTED
Gradient Boosting Matches Leading TADPOLE Challenge Submissions for Diagnosis But Not for ADAS-COG13 Forecasting
Disease progression modelling
AD/PD 2027 · BarcelonaACCEPTED
Causal Multimodal Digital Twins for Treatment-Relevant Neurodegeneration Trajectories
Disease progression modelling
AD/PD 2027 · BarcelonaACCEPTED
Group-Conditional Conformal Calibration Improves APOE4 Homozygote Coverage in Twenty-Four-Month Alzheimer Prognosis
Prognosis
AD/PD 2027 · BarcelonaACCEPTED
AI-Assisted Protocol Red-Teaming for Alzheimer's and Parkinson's Clinical Trials
Clinical trials
AD/PD 2027 · BarcelonaACCEPTED
Recursive Causal Discovery for Intervention-Relevant Alzheimer's and Parkinson's Targets
Target discovery
AD/PD 2027 · BarcelonaACCEPTED
Recursive Self-Driving Laboratories for Grounded Alzheimer's and Parkinson's Discovery
Drug discovery
AD/PD 2027 · BarcelonaACCEPTED
Neuro-Symbolic Falsification for Auditable Alzheimer's and Parkinson's Therapeutic Science
Drug discovery
AD/PD 2027 · BarcelonaACCEPTED
A Self-Improving Multimodal Design Stack for Neurodegenerative Therapeutics
Drug discovery